Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature
M. Internullo, V. Giannelli, L. Sardo, C. Antonaglia, T. Villani, E. Angelici, P. Palange Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, Rome, Italy. m.internullo@virgilio.it
Hydroxyurea is a cytotoxic agent widely used in the treatment of myeloproliferative disorders. It is considered a-well-tolerated antineoplastic drug, with a dose-related bone marrow suppression as main adverse effect. This report describes a patient with essential thrombocythemia who developed an interstitial pneumonitis and respiratory failure within 4 years from beginning therapy with hydroxyurea (HU). After discontinuing of HU. both clinical and radiological resolution of pneumonitis occurred. In conclusion, HU-induced pulmonary toxicity is a potentially life-threatening side effect.
Free PDF DownloadThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
M. Internullo, V. Giannelli, L. Sardo, C. Antonaglia, T. Villani, E. Angelici, P. Palange
Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature
Eur Rev Med Pharmacol Sci
Year: 2014
Vol. 18 - N. 2
Pages: 190-193